RA Cap­i­tal jumps in­to the melee on TTR amy­loi­do­sis, back­ing a $91M de­vel­op­ment plan for a Bridge­Bio drug

RA Cap­i­tal’s Ra­jeev Shah is gam­bling on a mid-stage drug for TTR amy­loi­do­sis, look­ing to take the field against a well ad­vanced slate of ri­vals from Pfiz­er, Al­ny­lam and Io­n­is.

Shah, one of the prin­ci­pals at RA, is join­ing the board at Bridge­Bio’s Ei­dos Ther­a­peu­tics af­ter lead­ing a $64 mil­lion fi­nanc­ing to pay for the mid-stage work on AG10. The mon­ey, they say, should take them to the thresh­old of a piv­otal pro­gram. In ad­di­tion to RA and Bridge­Bio, the slate of in­vestors in this fundrais­ing in­cludes Janus Hen­der­son, Viking Glob­al In­vestors, Ais­ling Cap­i­tal, Per­cep­tive Ad­vi­sors, Cor­morant As­set Man­age­ment and Amzak Health In­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER